Belzutifan induced strong responses in patients with von Hippel-Lindau disease-associated kidney cancer
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in patients with renal cell carcinomas (RCC) and non-renal cell carcinoma neoplasms associated with von Hippel-Lindau (VHL) disease. The study was published today in the New England Journal of...
Antihistamines can influence immunotherapy response by enhancing T cell activation
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication...
MD Anderson Research Highlights for November 17, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson Research Highlights: SITC 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting on radiation-induced immune activation in colorectal cancer, response biomarkers in soft tissue sarcoma, STING-mediated...
Collaboration on Data and Computational Sciences Announces Next Round of Projects to Advance Cancer Breakthroughs
The Oden Institute for Computational Engineering and Sciences (Oden Institute), The University of Texas MD Anderson Cancer Center ...
Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival benefit for patients with...
MD Anderson Research Highlights for November 3, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...